Crestwood Advisors Group LLC Has $18.73 Million Stake in IQVIA Holdings Inc. (NYSE:IQV)

Crestwood Advisors Group LLC reduced its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 44.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 95,316 shares of the medical research company’s stock after selling 76,979 shares during the period. Crestwood Advisors Group LLC’s holdings in IQVIA were worth $18,731,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in IQV. Capital Performance Advisors LLP acquired a new stake in shares of IQVIA during the third quarter worth $27,000. Synergy Asset Management LLC bought a new position in IQVIA during the fourth quarter worth about $33,000. Avior Wealth Management LLC boosted its holdings in IQVIA by 117.6% in the 3rd quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock valued at $38,000 after purchasing an additional 87 shares during the period. Assetmark Inc. grew its position in shares of IQVIA by 612.5% during the 3rd quarter. Assetmark Inc. now owns 228 shares of the medical research company’s stock worth $54,000 after purchasing an additional 196 shares in the last quarter. Finally, Concord Wealth Partners bought a new position in shares of IQVIA during the third quarter worth approximately $57,000. 89.62% of the stock is currently owned by institutional investors.

Insider Activity

In other IQVIA news, Director John G. Danhakl acquired 1,275 shares of IQVIA stock in a transaction that occurred on Tuesday, December 3rd. The shares were bought at an average price of $200.58 per share, with a total value of $255,739.50. Following the completion of the purchase, the director now directly owns 1,275 shares in the company, valued at $255,739.50. This trade represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders own 1.60% of the company’s stock.

Wall Street Analyst Weigh In

IQV has been the subject of several recent research reports. Robert W. Baird cut their price target on IQVIA from $212.00 to $210.00 and set a “neutral” rating for the company in a research note on Tuesday, January 21st. Morgan Stanley increased their target price on IQVIA from $245.00 to $250.00 and gave the stock an “overweight” rating in a report on Tuesday, February 11th. JPMorgan Chase & Co. dropped their price target on IQVIA from $240.00 to $232.00 and set an “overweight” rating for the company in a research note on Tuesday, February 18th. The Goldman Sachs Group reduced their price objective on shares of IQVIA from $280.00 to $250.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. Finally, Deutsche Bank Aktiengesellschaft decreased their target price on shares of IQVIA from $270.00 to $265.00 and set a “buy” rating on the stock in a report on Friday, November 1st. Four analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, IQVIA currently has an average rating of “Moderate Buy” and an average price target of $251.22.

IQVIA Price Performance

Shares of IQV opened at $190.94 on Monday. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. The stock has a market cap of $33.62 billion, a PE ratio of 25.46, a PEG ratio of 1.99 and a beta of 1.48. IQVIA Holdings Inc. has a 12-month low of $187.62 and a 12-month high of $261.73. The business has a 50-day simple moving average of $199.57 and a two-hundred day simple moving average of $216.25.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. Analysts anticipate that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.